Gastro
01 Jan 2013
A Study to Evaluate the Efficacy and Safety of CCX282-B in Subjects With Moderate to Severe Crohn’s Disease
The purpose of this study is to determine whether CCX282-B is effective in treating patients with moderate to severe Crohn’s Disease. Official Title A Multinational, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of CCX282-B in Subjects With Moderate to Severe Crohn’s Disease Conditions Crohn’s Disease…
Cancer
01 Jan 2013
A Single Arm Trial of Oxaliplatin and 5FU With Concurrent Radiation in Patients With Metastatic Rectal Cancer
This trial is a single-arm study for patients presenting with both local and metastatic adenocarcinoma of rectum. The aims of the trial are (1) to determine the tolerability rate, and (2) to determine toxicity rates, pelvic and distant response rates in patients with locally advanced rectal cancer in the presence…
Gastro
01 Jan 2013
A Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis
The purpose of this study is to compare the efficacy of visilizumab to placebo in subjects with intravenous steroid-refractory ulcerative colitis. Official Title A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis Conditions Ulcerative Colitis Study Type Interventional Study Design Treatment,…
Cancer
01 Jan 2013
A Randomised Trial of Preoperative Radiotherapy for Stage T3 Adenocarcinoma of Rectum
fThis is a multi-centre randomised trial comparing long course (LC) preoperative chemoradiation with short course (SC) preoperative radiotherapy for patients with localised T3 rectal cancer. Official Title A Randomised Trial of Preoperative Radiotherapy for Stage T3 Adenocarcinoma of Rectum Conditions Adenocarcinoma of Rectum Study Type Interventional Study Design…
Gastro
01 Jan 2013
A Study of Abatacept in Patients With Active Crohn’s Disease
The purpose of this clinical research study is to learn if abatacept can improve signs and symptoms of active Crohn’s Disease in patients who have not had an adequate response to other therapies. The safety of this treatment will also be studied. Official Title A Phase 3, Multi-Center, Randomized, Placebo-Controlled…
Gastro
01 Jan 2013
Study of Dexlansoprazole vs Placebo on the Ability to Maintain Healing in Subjects With Healed Erosive Esophagitis.
A 6-month study to assess the ability of daily treatment with dexlansoprazole 30mg, 60 mg or placebo in maintaining healing of erosive esophagitis. Official Title A Phase 3 Study to Evaluate the Safety and Efficacy of TAK-390MR (30 mg QD and 60 mg QD) Compared to Placebo in Maintenance of…
Blood
01 Jan 2013
Efficacy and Safety of Colesevelam in Pediatric Patients With Genetic High Cholesterol
This study will evaluate the lipid-lowering effect and safety of colesevelam therapy administered to heterozygous familial pediatric patients 10 through 17 years of age who are on a stable dose of a pediatric-approved statin monotherapy (atorvastatin, lovastatin, simvastatin or pravastatin), or who are treatment naive to lipid-lowering therapy. Official Title…
Blood
01 Jan 2013
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory Hodgkin’s or Non-Hodgkin’s Lymphoma
Phase II trial to study the effectiveness of combination chemotherapy followed by peripheral stem cell transplantation in treating children who have recurrent or refractory Hodgkin’s lymphoma or non-Hodgkin’s lymphoma. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Peripheral stem…
Blood
01 Jan 2013
PRELUDE:Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin
This clinical research study is to investigate the prevention of relapse in patients with diffuse large B cell lymphoma (DLBCL) using enzastaurin daily. This is a randomised trial which compares Enzastaurin to Placebo (dummy treatment), the chance of receiving Enzastaurin is 2 to 1. Official Title A Phase 3…
